{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kelly JD"],"funding":["National Institute of Allergy and Infectious Diseases","Department of Veterans Affairs Clinical Science Research and Development","National Institute of Allergy and Infectious Diseases (NIAID)","NIAID NIH HHS","CSRD VA"],"pagination":["222-230"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12448581"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["81(2)"],"pubmed_abstract":["<h4>Background</h4>Current coronavirus disease 2019 (COVID-19) vaccine recommendations in the United States (US) provide guidance for adults to receive at least annual variant-targeted vaccination. We sought to estimate the strength and durability of protection from annual variant-targeted vaccination against severe COVID-19 illness in individuals with vaccine-derived and hybrid immunity.<h4>Methods</h4>We emulated a target trial using an electronic health record-based, propensity score-matched (1:1) cohort of US Veterans. Booster-vaccinated adults were eligible for a variant-targeted messenger RNA (mRNA) booster starting 1 September 2022. Matched sets of those who did and did not receive the variant-targeted booster dose were identified on a weekly basis, and the cohort was followed until"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Annual Variant-Targeted Vaccination to Prevent Severe COVID-19 in Cohorts With Vaccine-Derived and Hybrid Immunity."],"pmcid":["PMC12448581"],"funding_grant_id":["K23 AI146268","CX002417","I01 CX002417","AI146268"],"pubmed_authors":["Austin CC","Byers AL","Hoggatt KJ","Kim HS","Tien PC","Bravata DM","Keyhani S","Leonard S","Lo NC","Lum EN","Kelly JD","Boscardin WJ","Austin PC"],"additional_accession":[]},"is_claimable":false,"name":"Annual Variant-Targeted Vaccination to Prevent Severe COVID-19 in Cohorts With Vaccine-Derived and Hybrid Immunity.","description":"<h4>Background</h4>Current coronavirus disease 2019 (COVID-19) vaccine recommendations in the United States (US) provide guidance for adults to receive at least annual variant-targeted vaccination. We sought to estimate the strength and durability of protection from annual variant-targeted vaccination against severe COVID-19 illness in individuals with vaccine-derived and hybrid immunity.<h4>Methods</h4>We emulated a target trial using an electronic health record-based, propensity score-matched (1:1) cohort of US Veterans. Booster-vaccinated adults were eligible for a variant-targeted messenger RNA (mRNA) booster starting 1 September 2022. Matched sets of those who did and did not receive the variant-targeted booster dose were identified on a weekly basis, and the cohort was followed until","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T15:15:11.259Z","creation":"2026-04-29T03:09:03.563Z"},"accession":"S-EPMC12448581","cross_references":{"pubmed":["40084406"],"doi":["10.1093/cid/ciaf124"]}}